Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations

doi:10.1073/pnas.1704531114

Comment

. 2017 Jun 6;114(23):E4524-E4526.

doi: 10.1073/pnas.1704531114. Epub 2017 May 16.

Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations

Pranesh Padmanabhan¹, Narendra M Dixit^{2

3}

Affiliations

¹ Queensland Brain Institute, University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia.
² Department of Chemical Engineering, Indian Institute of Science, Bangalore 560012, India; narendra@chemeng.iisc.ernet.in.
³ Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore 560012, India.

PMID: 28512229
PMCID: PMC5468610
DOI: 10.1073/pnas.1704531114

Comment

Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations

Pranesh Padmanabhan et al. Proc Natl Acad Sci U S A. 2017.

. 2017 Jun 6;114(23):E4524-E4526.

doi: 10.1073/pnas.1704531114. Epub 2017 May 16.

Authors

Pranesh Padmanabhan¹, Narendra M Dixit^{2

3}

Affiliations

¹ Queensland Brain Institute, University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia.
² Department of Chemical Engineering, Indian Institute of Science, Bangalore 560012, India; narendra@chemeng.iisc.ernet.in.
³ Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore 560012, India.

PMID: 28512229
PMCID: PMC5468610
DOI: 10.1073/pnas.1704531114

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Fig. 1.**
IIP of entry inhibitors compared with replication inhibitors. (A) Fits (lines) of the median effect equation, $\log_{10} [f_{a} / f_{u}] = m \log_{10} [D / {IC}_{50}]$ , to published experimental data (red circles) (–10). Here, $f_{a}$ and $f_{u}$ are the fractions of entry events affected and unaffected by EIs, respectively, obtained in the experiments (investigating viral entry using virus particles pseudotyped with HCV envelope proteins) by normalizing the luciferase activity at different concentrations of EI with luciferase activity in the absence of EI. Data digitization was performed using Engauge digitizer 9.7 and fitted using the tool REGRESS in MATLAB 2016b. The best-fit parameter estimates are listed in Table 1. (B) Comparison of the IIP₁₀₀ of the EIs in A with the IIP₁₀₀ of the replication inhibitors studied by Koizumi et al. (1).

See this image and copyright information in PMC

Comment in

Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.
Ohashi H, Koizumi Y, Fukano K, Wakita T, Perelson AS, Iwami S, Watashi K. Ohashi H, et al. Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. doi: 10.1073/pnas.1705234114. Epub 2017 May 16. Proc Natl Acad Sci U S A. 2017. PMID: 28512226 Free PMC article. No abstract available.

Comment on

Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.
Koizumi Y, Ohashi H, Nakajima S, Tanaka Y, Wakita T, Perelson AS, Iwami S, Watashi K. Koizumi Y, et al. Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1922-1927. doi: 10.1073/pnas.1610197114. Epub 2017 Feb 7. Proc Natl Acad Sci U S A. 2017. PMID: 28174263 Free PMC article.

Cited by

Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.
Raja R, Baral S, Dixit NM. Raja R, et al. Immunol Rev. 2018 Sep;285(1):55-71. doi: 10.1111/imr.12689. Immunol Rev. 2018. PMID: 30129199 Free PMC article. Review.
Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.
Padmanabhan P, Desikan R, Dixit NM. Padmanabhan P, et al. PLoS Comput Biol. 2020 Dec 8;16(12):e1008461. doi: 10.1371/journal.pcbi.1008461. eCollection 2020 Dec. PLoS Comput Biol. 2020. PMID: 33290397 Free PMC article.
Building a mechanistic mathematical model of hepatitis C virus entry.
Kalemera M, Mincheva D, Grove J, Illingworth CJR. Kalemera M, et al. PLoS Comput Biol. 2019 Mar 18;15(3):e1006905. doi: 10.1371/journal.pcbi.1006905. eCollection 2019 Mar. PLoS Comput Biol. 2019. PMID: 30883541 Free PMC article.
Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.
Raja R, Pareek A, Newar K, Dixit NM. Raja R, et al. PLoS Pathog. 2019 Apr 1;15(4):e1007701. doi: 10.1371/journal.ppat.1007701. eCollection 2019 Apr. PLoS Pathog. 2019. PMID: 30934020 Free PMC article.
Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.
Ohashi H, Koizumi Y, Fukano K, Wakita T, Perelson AS, Iwami S, Watashi K. Ohashi H, et al. Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. doi: 10.1073/pnas.1705234114. Epub 2017 May 16. Proc Natl Acad Sci U S A. 2017. PMID: 28512226 Free PMC article. No abstract available.

See all "Cited by" articles

References

1. Koizumi Y, et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci USA. 2017;114:1922–1927. - PMC - PubMed
1. Jilek BL, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med. 2012;18:446–451. - PMC - PubMed
1. Colpitts CC, Baumert TF. Hepatitis C virus cell entry: A target for novel antiviral strategies to address limitations of direct acting antivirals. Hepatol Int. 2016;10:741–748. - PMC - PubMed
1. Baldick CJ, et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 2010;6:e1001086. - PMC - PubMed
1. Coburn GA, et al. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. PLoS One. 2012;7:e35351. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Koizumi Y, et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci USA. 2017;114:1922–1927. - PMC - PubMed

[2] Koizumi Y, et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci USA. 2017;114:1922–1927. - PMC - PubMed

[3] Jilek BL, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med. 2012;18:446–451. - PMC - PubMed

[4] Jilek BL, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med. 2012;18:446–451. - PMC - PubMed

[5] Colpitts CC, Baumert TF. Hepatitis C virus cell entry: A target for novel antiviral strategies to address limitations of direct acting antivirals. Hepatol Int. 2016;10:741–748. - PMC - PubMed

[6] Colpitts CC, Baumert TF. Hepatitis C virus cell entry: A target for novel antiviral strategies to address limitations of direct acting antivirals. Hepatol Int. 2016;10:741–748. - PMC - PubMed

[7] Baldick CJ, et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 2010;6:e1001086. - PMC - PubMed

[8] Baldick CJ, et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 2010;6:e1001086. - PMC - PubMed

[9] Coburn GA, et al. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. PLoS One. 2012;7:e35351. - PMC - PubMed

[10] Coburn GA, et al. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. PLoS One. 2012;7:e35351. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations

Affiliations

Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations

Authors

Affiliations

Conflict of interest statement

Figures

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical